Eli Lilly retatrutide shows better weight loss than Novo Nordisk Ozempic in new study
Eli Lilly announced that its investigational drug retatrutide outperformed Novo Nordisk's Ozempic in lowering blood sugar and reducing weight during a large diabetes trial.
Study results favor the new drug
The company reported that retatrutide was more effective at cutting weight than the competitor medication. Researchers also found the investigational treatment lowered blood sugar levels more effectively than Ozempic in this head-to-head comparison. These findings come from a large study involving participants with diabetes.
Lilly shares the positive data
Eli Lilly released the results of this investigation to the public today. The pharmaceutical firm stated that its triple-G drug demonstrated superior performance in these specific health metrics. Novo Nordisk's Ozempic served as the benchmark for comparison in this research project.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.